Peak Bio, Inc. announced that it entered into a subscription agreement for private placement of 50,000 common shares at an issue price of $10 per share for gross proceeds of $500,000 on December 30, 2022. The company will also issue 46,500 warrants to purchase common shares, at an exercise price of $0.01 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | -.--% | -.--% | -95.41% |
03-05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
02-16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 199K | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced that it expects to receive $0.5 million in funding